- Home
- RERE vs KALV Comparison
RERE vs KALV Comparison
Compare RERE & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | KALV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.6M | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RERE | KALV |
|---|---|---|
| Price | $4.75 | $26.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 627.9K | ★ 4.1M |
| Earning Date | 05-19-2026 | 07-09-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $25.70 | $185.42 |
| Revenue Next Year | $22.93 | $59.23 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $2.41 | $9.83 |
| 52 Week High | $6.47 | $26.85 |
Technical Indicators
Market Signals| Indicator | RERE | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 75.25 |
| Support Level | $4.23 | $14.66 |
| Resistance Level | $4.89 | N/A |
| Average True Range (ATR) | 0.18 | 0.57 |
| MACD | 0.02 | 0.45 |
| Stochastic Oscillator | 67.91 | 98.41 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.